Improvement of Glycemic Control by 1 Year of Insulin Therapy Leads to a Sustained Decrease in sE-Selectin Concentrations in Type 2 Diabetes
- Leena Ryysy, MD and
- Hannele Yki-Järvinen, MD, FRCP
Abstract
OBJECTIVE—To examine whether and how improvement of glycemic control by long-term insulin therapy decreases endothelial activation as measured by serum levels of the soluble adhesion molecules sE-selectin and vascular cell adhesion molecule (VCAM-1) and whether the drug used to lower blood glucose in addition to insulin influences such a response.
RESEARCH DESIGN AND METHODS—Circulating adhesion molecules were measured before and after 3 and 12 months of therapy in 81 patients with type 2 diabetes and 41 subjects without diabetes. The patients were treated with bedtime administration of NPH insulin combined with either glibenclamide (n = 19), metformin (n = 17), glibenclamide and metformin (n = 17), or morning administration of NPH insulin (n = 23).
RESULTS—Before insulin therapy, serum sE-selectin level was 71% higher in the patients with type 2 diabetes (77 ± 4 ng/ml) than in the normal subjects (45 ± 3 ng/ml, P < 0.001), whereas levels of sVCAM-1 were comparable (420 ± 25 vs. 400 ± 11 ng/ml, respectively). Glycemic control in all patients improved as judged from a decrease in HbA1c from 9.7 ± 0.2 to 7.6 ± 0.1% (P < 0.001). sE-selectin decreased to 67 ± 4 ng/ml by 3 months (P < 0.001 vs. 0 months) and then remained unchanged until 12 months (70 ± 4 ng/ml, P < 0.001 vs. 0 months). sVCAM-1 levels at 12 months was similar to those at 0 months (416 ± 25 ng/ml). The change in glycemic control, measured by HbA1c, but not in other parameters, was correlated with the change of sE-selectin (r = 0.41, P < 0.001) within the patients with type 2 diabetes. The decreases in sE-selectin were not different between the various treatment groups.
CONCLUSIONS—We conclude that improvement in glycemic control by administration of insulin alone or insulin combined with either glibenclamide, metformin, or both agents induces a sustained decrease in sE-selectin, the magnitude of which seems to be dependent on the degree of improvement in glycemia. These data suggest that sE-selectin might provide a marker of effects of treatment of chronic hyperglycemia on endothelial activation.
- BI, bedtime insulin
- ICAM-1, intercellular adhesion molecule
- MET, metformin
- MI, morning insulin
- SU, sulfonylurea
- VCAM-1, vascular cell adhesion molecule
Footnotes
-
Address correspondence and reprint requests to Hannele Yki-Järvinen, MD, FRCP, Department of Medicine, Division of Diabetes, University of Helsinki, Haartmaninkatu 4, P.O. Box 340, FIN-00029 HUCH, Helsinki, Finland. E-mail: ykijarvi{at}helsinki.fi.
Received for publication 8 August 2000 and accepted in final form 15 November 2000.
A table elsewhere in this issue shows conventional and Système International (SI) units and conversion factors for many substances.
